ABSTRACT Many factors affect an individual’s response to a drug, and large inter-ethnic, intra-ethnic, and even intra-individual variations exist. These variations may affect both the therapeutic response to a drug, and the side effects that the patient experiences. It is very desirable to be able to predict these variations in response or to ensure that these variations are as small as possible. Using pharmacokinetic and pharmacodynamic information may increase the accuracy of response prediction. The clinical benefit obtained from adjuvant treatment with tamoxifen might be reduced in patients who have either a particular Cytochrome P450 (CYP) 2D6 genetic polymorphism or who are taking paroxetine, a strong inhibitor of CYP2D6. In this review, we summarize current knowledge in the field of pharmacogenomics and pharmacokinetics as it relates to selective estrogen receptor modulators, focusing particularly on clinical data.
View Full Article
|